Bleakley Financial Group LLC Makes New $481,000 Investment in Bicara Therapeutics Inc. $BCAX

Bleakley Financial Group LLC acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 30,478 shares of the company’s stock, valued at approximately $481,000. Bleakley Financial Group LLC owned about 0.06% of Bicara Therapeutics as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Schroder Investment Management Group boosted its position in shares of Bicara Therapeutics by 921.0% during the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after acquiring an additional 383,681 shares during the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in Bicara Therapeutics by 160.9% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock valued at $922,000 after purchasing an additional 61,201 shares in the last quarter. Artisan Partners Limited Partnership purchased a new stake in Bicara Therapeutics during the second quarter valued at $3,742,000. SCS Capital Management LLC bought a new position in Bicara Therapeutics during the second quarter valued at $496,000. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in shares of Bicara Therapeutics by 119.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock worth $75,000 after buying an additional 4,417 shares in the last quarter.

Analyst Ratings Changes

BCAX has been the topic of several recent research reports. Wells Fargo & Company upped their target price on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Citigroup initiated coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating for the company. HC Wainwright reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, Citizens Jmp initiated coverage on Bicara Therapeutics in a report on Thursday, January 29th. They set a “market perform” rating and a $31.00 price target on the stock. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $28.33.

Insider Buying and Selling at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 3,828 shares of Bicara Therapeutics stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $18.10, for a total transaction of $69,286.80. Following the completion of the sale, the chief operating officer owned 210,164 shares in the company, valued at $3,803,968.40. This trade represents a 1.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Ivan Hyep sold 1,882 shares of the business’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $18.15, for a total transaction of $34,158.30. Following the completion of the sale, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at approximately $2,638,193.25. This trade represents a 1.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 18,359 shares of company stock valued at $339,630. Corporate insiders own 15.50% of the company’s stock.

Bicara Therapeutics Stock Performance

Shares of BCAX stock opened at $17.51 on Thursday. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $19.71. The firm has a market capitalization of $959.20 million, a P/E ratio of -7.82 and a beta of -0.79. The stock has a 50 day moving average price of $16.43 and a 200 day moving average price of $15.45.

Bicara Therapeutics Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.